BVC.L

BATM Advanced Communications Ltd.
BATM Advanced Comm - Notice of AGM and Proposed Director Appointment
14th November 2024, 11:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2814M
BATM Advanced Communications Ld
14 November 2024
 

LEI: 213800FLQUB9J289RU66

14 November 2024

 

BATM Advanced Communications Limited

("BATM" or "the Group") 

 

Notice of Annual General Meeting and

Proposed Director Appointment

 

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, gives notice that the Annual General Meeting ("AGM" or the "Meeting") of the Group is to be held at 12.00pm Israel time (10.00am UK time) on 19 December 2024 at the Group's registered office at 4 Ha'harash Street, Nave Ne'eman Industrial Area, P.O.B. 7318, 4524075 Hod Hasharon, Israel.

 

In order to enable shareholder engagement and participation for those unable to physically attend the Meeting, shareholders will be able to access the Meeting via videoconference.

 

Among the resolutions to be proposed to the AGM is a resolution appointing Dr. Shmuel (Muli) Ben-Zvi as a Non-executive Director of the Group to take effect from the conclusion of the Meeting.

 

Dr. Shmuel (Muli) Ben Zvi was elected Chairman of the board of Bank Leumi, the largest banking corporation in Israel, in October 2023 for the final year of his nine-year tenure as a director. At Bank Leumi, he was a member of the board's audit, risk management, credit, technology and strategy committees. Dr. Ben Zvi has extensive executive and board experience across multiple industries, including currently being a director of Protalix Biotherapeutics (NYSE American: PLX) and previously of Sol-Gel Technologies (NASDAQ: SLGL) and VBL Therapeutics (NASDAQ: VBLT). From 2004 to 2014, he held a number of managerial positions at Teva Pharmaceuticals (NASDAQ and TASE: TEVA), including Vice President of Strategy and Vice President of Finance.

 

In accordance with Israeli Companies Law, the Group requires shareholder approval to appoint a new Non-executive Director. The required disclosures pursuant to UK Listing Rules 6.4.8 in relation to Dr. Ben Zvi will be made in due course subject to his appointment.

 

Further information on the resolutions, notes and details on how to attend the AGM via videoconference can be found in the Notice of AGM that, along with forms of proxy and direction, has today been made available on BATM's website at: www.batm.com.  

 

 

Enquiries

 

BATM Advanced Communications


Moti Nagar, Chief Executive Officer

+972 9866 2525                 

Ran Noy, Chief Financial Officer




Shore Capital


Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)

+44 20 7408 4050 



Gracechurch Group


Harry Chathli, Claire Norbury

+44 20 4582 3500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOABZLFFZFLZFBB]]>
TwitterFacebookLinkedIn